SCYX News and Press, SCYNEXIS Inc. From 01/09/23

Summary Scynexis has performed terribly during 2022 due to continued disappointment in earnings and sales ramp. New labels, including black-boxed warnings, could further hamper the slow commercial adoption of VVC indication, especially in the retail setting. We do not believe rVVC w...

BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC. Approval is based on pivotal Phase 3 CANDLE data demonstrating statistically significant supe...

Researchers to study the potential of SCY-247 to fight Candida auris (C.auris) , a multidrug-resistant pathogen named as an “urgent threat” by the Centers for Disease Control (CDC) and included in the “critital priority group” on the World Health Organization (WHO)...

BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target Candida species , including Candida auris, and Aspergillus species. Ibrexafungerp, a first-in-class, broad-spectrum oral/IV a...

SCYNEXIS, Inc. (SCYX) Q3 2022 Results Conference Call November 9, 2022 08:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr. Marco Taglietti - President & CEO Dr. David Angulo - Chief Medical Officer Ivor Macleod - Chief Financial...

SCYNEXIS press release ( NASDAQ: SCYX ): Q3 GAAP EPS of -$0.62 misses by $0.12 . Revenue of $1.56M (+200.0% Y/Y) misses by $0.5M . Cash, cash equivalents and short-term investments totaled $96.1 million on September 30, 2022, compared to $104.5 million in cash ...

SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications. Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer. Marco Taglietti, M.D., t...

JERSEY CITY, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced the publication of a review article highlighting ...

Clinical cure rates, in the pooled analysis, were statistically significantly greater for ibrexafungerp when compared with placebo (p < 0.0001). In the pooled analysis, patients receiving ibrexafungerp experienced significantly higher rates of clinical improvement, complete sym...

JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 ...